Jump Financial LLC Sells 31,687 Shares of Evolus, Inc. (NASDAQ:EOLS)

Jump Financial LLC decreased its holdings in Evolus, Inc. (NASDAQ:EOLS) by 42.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 43,100 shares of the company’s stock after selling 31,687 shares during the period. Jump Financial LLC owned 0.07% of Evolus worth $476,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in EOLS. Geode Capital Management LLC boosted its stake in Evolus by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 1,214,590 shares of the company’s stock worth $13,412,000 after purchasing an additional 3,969 shares during the period. Schroder Investment Management Group grew its stake in Evolus by 2.5% during the fourth quarter. Schroder Investment Management Group now owns 1,040,440 shares of the company’s stock valued at $11,330,000 after acquiring an additional 25,480 shares in the last quarter. Lord Abbett & CO. LLC grew its stake in Evolus by 23.4% during the third quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock valued at $16,126,000 after acquiring an additional 188,685 shares in the last quarter. Rice Hall James & Associates LLC increased its holdings in Evolus by 4.8% in the 4th quarter. Rice Hall James & Associates LLC now owns 948,281 shares of the company’s stock valued at $10,469,000 after acquiring an additional 43,381 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Evolus by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 421,481 shares of the company’s stock worth $4,653,000 after purchasing an additional 2,905 shares in the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Insider Activity

In related news, Director Karah Herdman Parschauer sold 12,888 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total transaction of $167,415.12. Following the completion of the sale, the director now directly owns 32,183 shares of the company’s stock, valued at approximately $418,057.17. This trade represents a 28.59 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the company’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $60,147.36. Following the completion of the transaction, the chief marketing officer now directly owns 95,671 shares in the company, valued at $1,268,597.46. This trade represents a 4.53 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 60,575 shares of company stock valued at $794,369. 6.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Evolus in a report on Wednesday, April 9th. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research note on Thursday, April 10th. Barclays increased their target price on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. Finally, BTIG Research began coverage on shares of Evolus in a research report on Thursday, April 17th. They issued a “buy” rating and a $21.00 price target on the stock. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Evolus presently has an average rating of “Buy” and an average target price of $23.75.

Evolus Price Performance

Shares of Evolus stock opened at $11.55 on Friday. The stock has a 50 day moving average price of $12.32 and a 200-day moving average price of $12.98. Evolus, Inc. has a one year low of $8.67 and a one year high of $17.82. The stock has a market cap of $734.43 million, a price-to-earnings ratio of -12.69 and a beta of 0.97. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.